Bioventus Statistics

Total Valuation

Bioventus has a market cap or net worth of $816.97 million. The enterprise value is $1.07 billion.

Market Cap	816.97M
Enterprise Value	1.07B

Important Dates

The next estimated earnings date is Wednesday, August 5, 2026, before market open.

Earnings Date	Aug 5, 2026
Ex-Dividend Date	n/a

Share Statistics

Bioventus has 83.53 million shares outstanding. The number of shares has increased by 7.22% in one year.

Current Share Class	67.75M
Shares Outstanding	83.53M
Shares Change (YoY)	+7.22%
Shares Change (QoQ)	+1.08%
Owned by Insiders (%)	3.14%
Owned by Institutions (%)	38.97%
Float	33.31M

Valuation Ratios

The trailing PE ratio is 24.26 and the forward PE ratio is 12.46. Bioventus's PEG ratio is 1.13.

PE Ratio	24.26
Forward PE	12.46
PS Ratio	1.42
Forward PS	1.33
PB Ratio	3.50
P/TBV Ratio	n/a
P/FCF Ratio	8.12
P/OCF Ratio	7.94
PEG Ratio	1.13

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.22, with an EV/FCF ratio of 10.63.

EV / Earnings	37.55
EV / Sales	1.86
EV / EBITDA	13.22
EV / EBIT	17.75
EV / FCF	10.63

Financial Position

The company has a current ratio of 1.69, with a Debt / Equity ratio of 1.23.

Current Ratio	1.69
Quick Ratio	1.06
Debt / Equity	1.23
Debt / EBITDA	3.34
Debt / FCF	2.87
Interest Coverage	2.59

Financial Efficiency

Return on equity (ROE) is 16.46% and return on invested capital (ROIC) is 12.36%.

Return on Equity (ROE)	16.46%
Return on Assets (ROA)	5.61%
Return on Invested Capital (ROIC)	12.36%
Return on Capital Employed (ROCE)	11.99%
Weighted Average Cost of Capital (WACC)	7.53%
Revenue Per Employee	$613,085
Profits Per Employee	$30,300
Employee Count	940
Asset Turnover	0.86
Inventory Turnover	2.04

Taxes

Income Tax	-899,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +46.19% in the last 52 weeks. The beta is 0.67, so Bioventus's price volatility has been lower than the market average.

Beta (5Y)	0.67
52-Week Price Change	+46.19%
50-Day Moving Average	9.59
200-Day Moving Average	8.24
Relative Strength Index (RSI)	60.27
Average Volume (20 Days)	706,335

Short Selling Information

The latest short interest is 1.84 million, so 2.21% of the outstanding shares have been sold short.

Short Interest	1.84M
Short Previous Month	1.58M
Short % of Shares Out	2.21%
Short % of Float	5.53%
Short Ratio (days to cover)	3.04

Income Statement

In the last 12 months, Bioventus had revenue of $576.30 million and earned $28.48 million in profits. Earnings per share was $0.40.

Revenue	576.30M
Gross Profit	395.87M
Operating Income	60.26M
Pretax Income	33.64M
Net Income	28.48M
EBITDA	80.90M
EBIT	60.26M
Earnings Per Share (EPS)	$0.40

Full Income Statement

Balance Sheet

The company has $35.85 million in cash and $288.42 million in debt, giving a net cash position of -$252.57 million or -$3.02 per share.

Cash & Cash Equivalents	35.85M
Total Debt	288.42M
Net Cash	-252.57M
Net Cash Per Share	-$3.02
Equity (Book Value)	234.27M
Book Value Per Share	2.79
Working Capital	101.72M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $102.94 million and capital expenditures -$2.31 million, giving a free cash flow of $100.63 million.

Operating Cash Flow	102.94M
Capital Expenditures	-2.31M
Depreciation & Amortization	20.64M
Net Borrowing	-9.15M
Free Cash Flow	100.63M
FCF Per Share	$1.20

Full Cash Flow Statement

Margins

Gross margin is 68.69%, with operating and profit margins of 10.46% and 4.94%.

Gross Margin	68.69%
Operating Margin	10.46%
Pretax Margin	5.84%
Profit Margin	4.94%
EBITDA Margin	14.04%
EBIT Margin	10.46%
FCF Margin	17.46%

Dividends & Yields

Bioventus does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.22%
Shareholder Yield	-7.22%
Earnings Yield	3.49%
FCF Yield	12.32%

Analyst Forecast

The average price target for Bioventus is $14.80, which is 51.33% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$14.80
Price Target Difference	51.33%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (3Y)	6.45%
EPS Growth Forecast (3Y)	16.31%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Bioventus has an Altman Z-Score of 1.38 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.38
Piotroski F-Score	8